Get Flat 20% Discount on All Medications
  • Danielle Jolla, United States says, "I love your online pharmacy Because of your quick shipping and reasonable prices."
  • Jill Barrella, United States says, "Seemed easy to purchase, reasonable prices. Good customer service when I used it."
  • Brian Pavey, United States says, "I am very satisfied with IDM and plan on making more purchases in the future. IDMs prices are low which makes it very compelling to use over conventional pharmacies with high copays and more restrictions continually implemented."
  • Eric Gonzales, United States says, "The website is very user friendly, there is a lot of variety and checking out was easy."
  • Albert Martinez, United States says, "Very organized and efficient concerning delivery and products are great. Very satisfied, impressed with delivery and product."
  • Natalie Wallace, United States says, "I absolutely love getting my medications at a great price and I always get that here. And I recommend this site to my family and friends."
  • Ask our pharmacist, if you have any questions related to your medications
    Click to find International Shipping charges at our pharmacy.
    Shop & Earn @ InternationalDrugMart
    Easy and secure shopping @
    Get your instant Coupon now!
    Price challenge
    You can find the latest happening of our pharmacy Visit to discuss on various diseases and conditions
    Follow us on Twitter
    You are here: Home > Pharmacy News | Health Articles/Tips > Ranbaxy Laboratories > September 08, 2009

      Ranbaxy's Romania unit to market osteoporosis drug


      Pharma firm Ranbaxy Laboratories today said its Romanian arm will market Evista, a drug used for treating Osteoporosis.

      Terapia SA (Terapia Ranbaxy), a subsidiary of the company would market the osteoporosis medication drug in Romania, Ranbaxy Laboratories, which was acquired by Daiichi Sankyo last year, said in a filing to the Bombay Stock Exchange.

      "The launch of Evista by Terapia Ranbaxy in Romania marks our first international endeavour as a global partnership. Terapia Ranbaxy is a strong player in Europe, and we will provide a unique platform to Daiichi Sankyo for the launch of Evista, and many more new products in the future," Ranbaxy CEO and Managing Director Atul Sobti said.

      Terapia Ranbaxy is the largest generic pharmaceutical company.

      "We continue to explore other collaborations with Ranbaxy that will help optimise our growth," Daiichi Sankyo President and CEO Takashi Shoda said.

      In 2006, Daiichi Sankyo acquired the marketing and distribution rights for Evista, an osteoporosis treatment, in six European countries from Eli Lilly and Company, it said.

      In 2008, Daiichi Sankyo acquired additional rights for the drug covering all remaining countries in Europe, with the exception of Greece, the filing said.

      Shares of Ranbaxy Laboratories were trading at Rs 332 on the BSE, up 1.34 per cent from previous close.

      September 08, 2009


      Share this Article!

    Back to top^